FDA Approves Fayuvi (rebisufligene etisparvovec-hopf) Gene Therapy for the Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
RegulatoryapprovedFayuviPositive
AI Analysis
Summary
Ultragenyx Pharmaceutical announced FDA approval of Fayuvi (rebisufligene etisparvovec-hopf), a gene therapy for Sanfilippo Syndrome Type A (MPS IIIA). This marks a significant regulatory milestone for the rare genetic disorder treatment.
Outcome Details
FDA granted standard full approval
Importance:9/10
Sentiment:
0.95
FDA approvalgene therapyrare diseaseMPS IIIASanfilippo Syndrome
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on September 17, 2026 10:09 PM